+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Mantle Cell Lymphoma - Pipeline Insight, 2024

  • PDF Icon

    Clinical Trials

  • 80 Pages
  • June 2024
  • Region: Global
  • DelveInsight
  • ID: 4989357
This “Mantle Cell Lymphoma- Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Mantle Cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Mantle Cell Lymphoma: Understanding

Mantle Cell Lymphoma: Overview

Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphomas (NHLs) characterized by an (11,14) translocation resulting in overexpression of the cyclin D1 (CCND1) gene. The variety of morphologic variants may make this a challenging diagnosis, although some cases are uncomplicated. Many individuals with mantle cell lymphoma may not have symptoms (asymptomatic) during early stages of the disease. However, affected individuals may eventually seek medical attention due to persistent, usually painless, swelling of certain lymph nodes, particularly nodes within the neck and throat region (e.g., Waldeyer’s ring).

MCL is characterized by reciprocal chromosomal translocation t(11;14)(q13:q32), resulting in the juxtapositioning of cyclin D1 locus to immunoglobulin heavy chain gene locus. This leads to constitutive expression of cyclin D1 (CCND1), which plays a significant role in tumor cell proliferation via cell cycle dysregulation, chromosomal instability, and epigenetic regulation. Rare cases without this translocation may have a CCND2 or 3 translocations. Hypothetical models of molecular subtypes have been proposed based on the cell of origin that correlates to clinical phenotypes. Arising from naive B cells that have no or limited iGVH mutations and express SOX 11 are the classical MCL or aggressive MCL. SOX 11 is a neural transcription factor reported to block terminal B cell differentiation. Arising from antigen-experienced B cells that have undergone IGVH somatic hypermutations and typically SOX 11 negative and genetically stable B cells are the indolent variant of MCL.

Mantle cell lymphoma is diagnosed based upon a detailed patient history, thorough clinical evaluation and a variety of specialized tests, including a biopsy of an affected lymph node or the bone marrow. Such testing is necessary to confirm the specific type (and subtype) of NHL present, to assess the nature and extent of the disease, and to determine the most appropriate treatments.

Treatment for mantle cell lymphoma typically involves a multifaceted approach tailored to each patient's specific circumstances. It commonly includes chemotherapy, which uses potent drugs to target and destroy cancer cells, along with immunotherapy drugs like rituximab to boost the body's immune response against the lymphoma. Additionally, targeted therapies such as ibrutinib and stem cell transplants may be utilized, particularly for those with aggressive disease or younger patients. Radiation therapy may be employed to target specific areas of lymphoma involvement. Participation in clinical trials may also offer innovative treatment options. The treatment plan is carefully crafted by healthcare professionals in collaboration with the patient, taking into account factors such as disease stage, overall health, and individual preferences. Regular monitoring and follow-up care are crucial components of managing mantle cell lymphoma to track treatment response and address any side effects effectively.

"Mantle Cell Lymphoma- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Mantle Cell Lymphoma pipeline landscape is provided which includes the disease overview and Mantle Cell Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Mantle Cell Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Mantle Cell Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Mantle Cell Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Mantle Cell Lymphoma.

Mantle Cell Lymphoma Emerging Drugs Chapters

This segment of the Mantle Cell Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Mantle Cell Lymphoma Emerging Drugs

Venetoclax: AbbVie

Venetoclax is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing their natural death or self-destruction process, called apoptosis. VENCLYXTO targets the BCL-2 protein and works to help restore the process of apoptosis.
Venetoclax is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the US and by AbbVie outside of the US. Together, the companies are committed to BCL-2 research and to studying venetoclax in clinical trials across several blood and other cancers. Venetoclax is approved in more than 80 countries, including the US. Currently the product is in Phase III for mantle cell lymphoma.

Ixazomib: Takeda

Ixazomib belongs to a class of drugs called proteasome inhibitors, which work by blocking the action of proteasomes, cellular structures responsible for breaking down proteins. By inhibiting proteasomes, ixazomib helps to disrupt the growth and survival of cancer cells. Currently, the product is in the Phase II stage of its development for the treatment of mantle cell lymphoma.

ADI-001: Adicet Bio

ADI-001 is an investigational allogeneic gamma delta CAR T cell therapy being developed as a potential treatment for relapsed or refractory B-cell NHL. ADI-001 targets malignant B-cells via an anti-CD20 CAR and via the gamma delta innate and T cell endogenous cytotoxicity receptors. Gamma delta T cells engineered with an anti-CD20 CAR have demonstrated potent antitumor activity in preclinical models, leading to long-term control of tumor growth. ADI-001 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of relapsed or refractory B-cell NHL. Currently, the drug is in the Phase I stage of its development for the treatment of mantle cell lymphoma.

Mantle Cell Lymphoma: Therapeutic Assessment

This segment of the report provides insights about the different Mantle Cell Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Mantle Cell Lymphoma

  • There are approx. 20+ key companies which are developing the therapies for Mantle Cell Lymphoma. The companies which have their Mantle Cell Lymphoma drug candidates in the most advanced stage, i.e. Phase III include, AbbVie.

Phases

This report covers around 22+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Route of Administration

Mantle Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Mantle Cell Lymphoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Mantle Cell Lymphoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Mantle Cell Lymphoma drugs.

Mantle Cell Lymphoma Report Insights

  • Mantle Cell Lymphoma Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Mantle Cell Lymphoma Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Mantle Cell Lymphoma drugs?
  • How many Mantle Cell Lymphoma drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Mantle Cell Lymphoma?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Mantle Cell Lymphoma therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Mantle Cell Lymphoma and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • AbbVie
  • Takeda
  • Adicet Bio
  • InnoCare Pharma Inc.
  • Guangzhou Lupeng Pharmaceutical Company LTD.
  • BeiGene
  • Gilead Sciences

Key Products

  • Venetoclax
  • Ixazomib
  • ADI-001
  • Orelabrutinib
  • LP-168
  • BGB-11417
  • KTE-X19


This product will be delivered within 1-3 business days.

Table of Contents

IntroductionExecutive Summary
Mantle Cell Lymphoma: Overview
  • Introduction
  • Symptoms
  • Pathophysiology
  • Diagnosis
  • Treatment
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Mantle Cell Lymphoma- Analytical Perspective
Late Stage Products (Phase III)
  • Comparative Analysis
Venetoclax: AbbVie
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
Ixazomib: Takeda
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
ADI-001: Adicet Bio
  • Product Description
  • Research and Development
  • Product Development Activities
Preclinical and Discovery Stage Products
  • Comparative Analysis
Product Name: Company Name
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Mantle Cell Lymphoma Key CompaniesMantle Cell Lymphoma Key ProductsMantle Cell Lymphoma- Unmet NeedsMantle Cell Lymphoma- Market Drivers and BarriersMantle Cell Lymphoma- Future Perspectives and ConclusionMantle Cell Lymphoma Analyst ViewsMantle Cell Lymphoma Key CompaniesAppendix
List of Tables
Table 1 Total Products for Mantle Cell Lymphoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Mantle Cell Lymphoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie
  • Takeda
  • Adicet Bio
  • InnoCare Pharma Inc.
  • Guangzhou Lupeng Pharmaceutical Company LTD.
  • BeiGene
  • Gilead Sciences